When the FDA Says Yes But the Market Says Maybe: A Gene Therapy Gamble

Maurice was pacing back and forth across his desk, occasionally pausing to hurl banana peels at a chart that refused to cooperate with his narrative.

You know that feeling when you win the lottery but someone forgot to tell you? That’s approximately where Rocket Pharmaceuticals (RCKT) found itself in late March 2026. The FDA handed them accelerated approval for KRESLADI, a gene therapy for severe Leukocyte Adhesion Deficiency-I in children—a genuinely rare, genuinely devastating genetic disorder where the immune system basically throws up its hands and surrenders. This is the kind of news biotech companies dream about. This is the catalyst. This is supposed to be the moment.

And the stock went down 8.9% anyway.

I sat there staring at the news wire, banana in hand, trying to figure out which universe I was living in. Approval for a gene therapy with unmet medical need? That’s a home run in biotech. That’s the whole game! And yet the market looked at this achievement the way I look at a banana that’s just slightly too brown—technically still good, but with visible reservations.

This is why I’m both fascinated and deeply cautious about Rocket Pharmaceuticals. There’s real science here. There’s real progress. There’s also a stock price that’s acting like it doesn’t believe any of it.

The Good Stuff (And It’s Actually Pretty Good)

Let me be clear about something first: Rocket Pharmaceuticals isn’t some shell company with a PowerPoint presentation and dreams. They’ve got 27 years of history, a pipeline of legitimate gene therapy programs addressing real genetic diseases, and they just cleared one of the biggest hurdles in biotech—FDA approval for a therapeutic product. KRESLADI is now approved for LAD-I, and even though it’s targeting a rare disease (which means the addressable market is smaller), you’re talking about a life-or-death therapy where there were literally no other options.

Think of gene therapy like a banana tree. Most of them are already established in the market, producing consistent fruit year after year. Gene therapy is the experimental orchard where you’re betting that new varieties will eventually produce remarkable fruit nobody’s ever tasted before. KRESLADI just became one of those actual fruits. The question is whether the market values it appropriately.

The pipeline behind KRESLADI is legitimately impressive too. We’re talking about programs targeting:

In vivo AAV programs (they fix the gene where it lives in your body): Danon disease in Phase 2 trials, which is a multi-organ disorder that kills people via heart failure. PKP2 Arrhythmogenic Cardiomyopathy in Phase 1. BAG3 Dilated Cardiomyopathy still in preclinical. These aren’t hypothetical. These are advancing.

Ex vivo lentiviral programs (they take cells out, fix them, put them back): Fanconi Anemia, Pyruvate Kinase Deficiency. These are sitting in preclinical to clinical stages, and they address diseases where even partial improvement changes lives fundamentally.

The commercial validation from Wedbush in early March—calling the company “significantly undervalued” as the cardiac pipeline advances—wasn’t some random analyst throwing darts. This is a serious analyst acknowledging what the pipeline actually represents.

The Confusing Part (And It’s Very Confusing)

Here’s where I had to actually sit down and think about this like I was peeling back layers of a particularly complex banana: Why would the FDA approval crater the stock?

The easy answer is market expectations. If everyone was expecting approval, the stock already priced it in. But looking at the 20-day momentum (+42.8%) that got Foxy excited, it seems like the market was absolutely expecting this. So why the reversal when it actually happened?

Three possibilities are sitting in my brain like competing banana-eating monkeys:

First: Commercial reality check. LAD-I is rare. We’re talking about dozens of children per year in the entire United States who qualify for treatment. That’s not a blockbuster market. That’s a niche therapy with a niche patient population. The market might be asking: “Okay, you got approval. But how many kids can you actually treat? And what does that mean for revenue?” Gene therapies for rare diseases are often priced astronomically—we’re potentially talking about multi-million-dollar-per-patient treatments—but volume is the constraint. The approved-market might be smaller than the stock price was betting on.

Second: The long game is still very long. KRESLADI is approved. That’s milestone one. But look at the rest of the pipeline. Danon disease is in Phase 2. Everything else is earlier. If you’re investing in Rocket because of KRESLADI, you’re looking at years before other programs mature. And in biotech, “years” is a long time to hold through clinical trial variance, manufacturing challenges, and the constant background anxiety that early-stage therapies create.

Third: Burn rate and funding runway. This is where I threw a banana at the wall. Rocket has negative free cash flow of $104 million annually. They have no revenue yet from approved products—KRESLADI was just approved. They’re burning cash like it’s going out of style, which means they’ll need to raise capital. And when you’re raising capital in biotech, the market has opinions about how dilutive that financing will be.

The Numbers That Matter (And the Ones That Don’t)

Let’s talk about what’s actually working in Rocket’s favor from a risk management standpoint. Beta is 0.574—that’s low. Really low. While the broader biotech sector is swinging wildly, Rocket’s actually moving more conservatively relative to the market. That’s the kind of stability you want when you’re in a high-risk sector. It’s like having a rope that doesn’t fray as easily, even if you’re still climbing a cliff.

Debt-to-equity at 8.974 is actually reasonable for a biotech company burning cash to develop therapies. Some would call that lean. Others would hyperventilate. I’m in the “reasonable for the sector” camp, especially since the company isn’t drowning in debt at insane interest rates.

The analyst consensus? Eleven analysts covering the stock, target price at $8.48, and the current price is sitting at $3.64. That’s meaningful upside if they’re right. That’s also a stock that’s been beaten down hard, which raises the question: Are these analysts being optimistic, or is the market being pessimistic?

Here’s what I can’t ignore though: Zero earnings. Negative cash flow. PE ratio that’s undefined because there are no profits. Forward PE is negative because the forward earnings projection is negative. This isn’t a company making money. This is a company spending money to develop therapies that they hope will eventually make money. That’s standard for clinical-stage biotech, but it means everything rides on clinical success and regulatory approval.

The Short Interest Plot Twist

Short interest is 4.64%. That’s elevated but not insane. There are definitely people betting against this company, which tells me the market’s skepticism isn’t universal, but it’s real. Short sellers are saying: “I think this stock is overvalued and will decline.” Interestingly, the stock already has declined from its 52-week high of $8.26 to $3.64. If the shorts set up their positions near that high, they’re already winning. But if they set up recently, they’re fighting the current momentum.

This matters because shorts can create explosive rallies when they’re forced to cover. If good clinical data comes out, or if another program gets FDA approval, shorts covering combined with genuine buying could create significant upside. That’s part of what might make this interesting, though it’s also a reminder that short squeezes aren’t investment theses.

The Real Question: Is This a Buy?

Foxy recommended entry at $4.97 with a target of $8.50. Current price is $3.64, which means you’re actually getting a better entry than Foxy suggested. That’s either a gift or a warning, depending on whether the market’s being too pessimistic or not pessimistic enough.

Here’s my honest take, and I’m adjusting my banana-reading glasses for this: Rocket Pharmaceuticals has legitimate science, real clinical progress, actual FDA approval, and a pipeline that could represent significant value if it advances successfully. But they’re in the messiest part of the biotech journey. They have one approved product with a small addressable market. They’re burning cash. They’ll need to raise capital, which will dilute shareholders. And their stock price reflects deep skepticism about whether the current pipeline will actually deliver.

That skepticism might be justified. Or it might be the market being too pessimistic about a company that just cleared a major regulatory hurdle and has multiple shots on goal in its pipeline.

The risk level is genuinely high—this is a biotech company where clinical trial failures could crater the stock. But the risk/reward math is interesting if you believe in the science and have patience for a multi-year hold.

I’m not saying don’t look at Rocket. I’m saying look at it with clear eyes about what it actually is: A clinical-stage biotech company that just achieved one win and is betting everything on whether the rest of the pipeline delivers. That’s exactly the kind of position that can produce 2x or 3x returns if things go right, or gut-wrenching losses if they don’t.

Maurice was swinging from the chandelier by the end of this analysis, which is how I know my brain is appropriately conflicted.

Disclaimer: Trained Market Money, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys—no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.

Next week on the Maurice Monitor: We’re peeling back the layers on a semiconductor company that’s playing a dangerous game with inventory. Can they navigate the supply chain banana peel, or are they slipping?

Maurice’s Final Word: “FDA approval is the appetizer, not the main course. Come back when the cash register starts ringing.”